Today Columbus Venture Partners announces the creation of Syngoi Technologies, a biotechnology company engaged in the production of synthetic DNA through a new enzymatic process, owned by the company, that addresses the needs of advanced therapies where DNA is the fundamental starting material. This is the case of gene therapy and mRNA-based vaccines, emerging therapeutic strategies where manufacturing is an important bottleneck. Syngoi has its own technology for the manufacture of its optimised synthetic DNA (orDNATM) which confers multiple...Read more
With the new investment fund, the managers plan to build two new plants in San Sebastian Columbus Venture Partners already has its second fund ready to invest in companies related to health sciences. It is in the registration phase at the National Securities Market Commission (CNMV) and will be operational shortly. The expected volume is 70 million euros, reports Expansión. According to Columbus executives, this new fund plans to provide continuity to the activity initiated by the previous one, which has five companies...Read more
This document is a simple guide, designed to quickly find information about SPRI subsidy programmes that are or will be available in...Read more
Síguenos y recibe en tu Linkedin información diaria segmentada
por sectores de actividad y países de interés para tomar las
decisiones más competitivas
Latest innovations and first-hand business models
you can check out the key points on our YouTube channel
Find the professionals that have
